Neoadjuvant chemotherapy for resectable colorectal liver metastases: What is the evidence? Results of a systematic review of comparative studies

被引:23
作者
Nigri, Giuseppe [1 ]
Petrucciani, Niccolo [1 ]
Ferla, Fabio [2 ]
La Torre, Marco [1 ]
Aurello, Paolo [1 ]
Ramacciato, Giovanni [1 ]
机构
[1] Univ Roma La Sapienza, St Andreas Hosp, Dept Surg, I-00189 Rome, Italy
[2] Osped Niguarda Ca Granda, Dept Surg, Milan, Italy
来源
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND | 2015年 / 13卷 / 02期
关键词
Liver metastases; Colorectal metastases; Neoadjuvant chemotherapy; Preoperative chemotherapy; Surgery; Hepatectomy; PERIOPERATIVE CHEMOTHERAPY; HEPATIC RESECTION; PREOPERATIVE CHEMOTHERAPY; CANCER; SURGERY; HEPATECTOMY; STRATEGIES; FOLFOX4;
D O I
10.1016/j.surge.2014.07.005
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The role of preoperative chemotherapy for resectable colorectal liver metastases is still highly controversial. The purpose of this systematic review is to summarize the current evidence on this topic. Methods: A systematic literature search was performed to identify all studies published from January 2003 up to and including January 2014 regarding patients with initially resectable colorectal liver metastases. Data were examined for information about indications, operation, neoadjuvant and adjuvant therapies, perioperative results, and survival. Results: Fourteen retrospective studies published between 2003 and 2014 satisfied the inclusion criteria, including 1607 patients who underwent pre-operative chemotherapy and liver resection (NEO-CHT group), and 1785 patients submitted to hepatectomy with or without post-operative chemotherapy (SURG group). Postoperative mortality rates ranged from 0 to 5% in the NEO-CHT group and from 0 to 4% in SURG group. Complications ranged from 7 to 63% in both groups. Adopted pre-operative chemotherapy protocols were highly heterogeneous. The 5-year overall survival rates ranged from 38.9 to 74% in the NEO-CHT group and from 20.7 to 56% in the SURG group, with no significant difference in seven of eight studies. Discussion: This review shows that there is a lack of clear evidence on the role of neoadjuvant chemotherapy in the. treatment of resectable colorectal metastases in the literature. The majority of studies were retrospective and there was high heterogeneity among them in the treatment protocols. The EORTC 40983 trial and the majority of retrospective studies did not find any overall survival advantage in patients treated with neoadjuvant therapy. Additional high-quality studies (randomized) are needed to shed light on this topic. (C) 2014 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 31 条
[1]   The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus [J].
Adam, Rene ;
De Gramont, Aimery ;
Figueras, Joan ;
Guthrie, Ashley ;
Kokudo, Norihiro ;
Kunstlinger, Francis ;
Loyer, Evelyne ;
Poston, Graeme ;
Rougier, Philippe ;
Rubbia-Brandt, Laura ;
Sobrero, Alberto ;
Tabernero, Josep ;
Teh, Catherine ;
Van Cutsem, Eric .
ONCOLOGIST, 2012, 17 (10) :1225-1239
[2]   Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases [J].
Allen, PJ ;
Kemeny, N ;
Jarnagin, W ;
DeMatteo, R ;
Blumgart, L ;
Fong, Y .
JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (01) :109-115
[3]  
[Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590
[4]   Comparison Between Perioperative and Postoperative Chemotherapy After Potentially Curative Hepatic Resection for Metastatic Colorectal Cancer [J].
Araujo, Raphael ;
Gonen, Mithat ;
Allen, Peter ;
Blumgart, Leslie ;
DeMatteo, Ronald ;
Fong, Yuman ;
Kemeny, Nancy ;
Jarnagin, William ;
D'Angelica, Michael .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (13) :4312-4321
[5]   Impact of Neoadjuvant Chemotherapy with FOLFOX/FOLFIRI on Disease-Free and Overall Survival of Patients with Colorectal Metastases [J].
Boostrom, Sarah Y. ;
Nagorney, David M. ;
Donohue, John H. ;
Harmsen, Scott ;
Thomsen, Kristine ;
Que, Florencia ;
Kendrick, Michael ;
Reid-Lombardo, Kaye M. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (11) :2003-2009
[6]   Surgical Strategies to Synchronous Colorectal Liver Metastases [J].
Brouquet, Antoine ;
Nordlinger, Bernard .
DIGESTIVE DISEASES, 2012, 30 :132-136
[7]   Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy [J].
Cucchetti, Alessandro ;
Ercolani, Giorgio ;
Cescon, Matteo ;
Di Gioia, Paolo ;
Peri, Eugenia ;
Brandi, Giovanni ;
Pellegrini, Sara ;
Pinna, Antonio Daniele .
LANGENBECKS ARCHIVES OF SURGERY, 2012, 397 (03) :397-405
[8]   "Liver-first" approach for synchronous colorectal liver metastases: is this a justifiable approach? [J].
De Rosa, A. ;
Gomez, D. ;
Brooks, A. ;
Cameron, I. C. .
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2013, 20 (03) :263-270
[9]   The Liver-First Approach to the Management of Colorectal Cancer With Synchronous Hepatic Metastases A Systematic Review [J].
Jegatheeswaran, Santhalingam ;
Mason, James M. ;
Hancock, Helen C. ;
Siriwardena, Ajith K. .
JAMA SURGERY, 2013, 148 (04) :385-391
[10]   Perioperative chemotherapy for resectable colorectal liver metastases: Where now? [J].
Jones, R. P. ;
Malik, H. Z. ;
Fenwick, S. W. ;
Poston, G. J. .
EJSO, 2013, 39 (08) :807-811